This HTML5 document contains 55 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n2http://linked.opendata.cz/resource/drugbank/drug/
dctermshttp://purl.org/dc/terms/
n15http://linked.opendata.cz/resource/mesh/concept/
foafhttp://xmlns.com/foaf/0.1/
n4http://linked.opendata.cz/resource/drugbank/company/
n6http://linked.opendata.cz/resource/drugbank/dosage/
n25http://linked.opendata.cz/resource/drugbank/drug/DB01276/identifier/wikipedia/
n22http://linked.opendata.cz/resource/drugbank/drug/DB01276/identifier/pharmgkb/
n10http://bio2rdf.org/drugbank:
admshttp://www.w3.org/ns/adms#
n17http://www.rxlist.com/cgi/generic/
n5http://linked.opendata.cz/resource/drugbank/patent/
n20http://wifo5-03.informatik.uni-mannheim.de/drugbank/resource/drugs/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n19http://linked.opendata.cz/resource/drugbank/medicinal-product/
owlhttp://www.w3.org/2002/07/owl#
n11http://linked.opendata.cz/resource/drugbank/drug/DB01276/identifier/kegg-drug/
n14http://linked.opendata.cz/ontology/mesh/
n3http://linked.opendata.cz/ontology/drugbank/
n18http://www.drugs.com/cdi/
n8http://linked.opendata.cz/resource/drugbank/drug/DB01276/identifier/drugbank/
n13http://linked.opendata.cz/resource/drugbank/property/
xsdhhttp://www.w3.org/2001/XMLSchema#
n12http://linked.opendata.cz/resource/drugbank/drug/DB01276/identifier/national-drug-code-directory/
n24http://linked.opendata.cz/resource/atc/
n23http://linked.opendata.cz/ontology/sukl/drug/

Statements

Subject Item
n2:DB01276
rdf:type
n3:Drug
n3:description
Exenatide, derived from a compound found in the saliva of the Gila monster, a large lizard native to the southwestern US, is a functional analog of Glucagon-Like Peptide-1 (GLP-1), a naturally occuring peptide.
n3:dosage
n6:271B6278-363D-11E5-9242-09173F13E4C5 n6:271B6279-363D-11E5-9242-09173F13E4C5 n6:271B6276-363D-11E5-9242-09173F13E4C5 n6:271B6277-363D-11E5-9242-09173F13E4C5
n3:generalReferences
# Heine RJ, Van Gaal LF, Johns D, Mihm MJ, Widel MH, Brodows RG: Exenatide versus insulin glargine in patients with suboptimally controlled type 2 diabetes: a randomized trial. Ann Intern Med. 2005 Oct 18;143(8):559-69. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/16230722
n3:group
approved investigational
n3:halfLife
Mean terminal half-life is 2.4 hours.
n3:indication
Indicated as adjunctive therapy to improve glycemic control in patients with Type 2 diabetes mellitus who are taking metformin, a sulfonylurea, or a combination of both, but have not achieved adequate glycemic control.
owl:sameAs
n10:DB01276 n20:DB01276
dcterms:title
Exenatide
adms:identifier
n8:DB01276 n11:D04121 n12:66780-210-07 n22:PA164749238 n25:Exenatide
n3:mechanismOfAction
Exenatide is a functional analog of the human incretin Glucagon-Like Peptide-1 (GLP-1). Incretins enhance glucose-dependent insulin secretion and exhibit other antihyperglycemic actions following their release into the circulation from the gut. The GLP-1 system increases insulin secretion only in the presence of elevated plasma glucose levels, avoiding inappropriately high insulin levels during fasting. The drug also moderates peak serum glucagon levels during hyperglycemic periods following meals, but does not interfere with glucagon release in response to hypoglycemia. Secondary effects of drug administration reduces the rate of gastric emptying and decreases food intake, mitigating the potential severity of hyperglycemic events after meals.
n3:packager
n4:271B626E-363D-11E5-9242-09173F13E4C5 n4:271B6271-363D-11E5-9242-09173F13E4C5 n4:271B6272-363D-11E5-9242-09173F13E4C5 n4:271B626F-363D-11E5-9242-09173F13E4C5 n4:271B6270-363D-11E5-9242-09173F13E4C5
n3:patent
n5:6872700 n5:5424286
n3:routeOfElimination
Nonclinical studies have shown that exenatide is predominantly eliminated by glomerular filtration with subsequent proteolytic degradation.
n3:synonym
AC002993 AC2993 Exenatide synthetic AC 2993 AC2993a Bydureon Byetta Exenatide Synthetic exendin-4 AC-2993
n3:toxicity
Effects of the overdoses included severe nausea, severe vomiting, and rapidly declining blood glucose concentrations.
n3:volumeOfDistribution
* 28.3 L
n3:synthesisReference
Matthieu Giraud, Anne-Sophie Droz, Stephane Varray, El Djouhar Rekai, Marie-Helene Brichard, Daniel Latassa, Christine Devijver, Pascal Gilles, Jeanne-Marie Cauvin, Fernando Albericio, Marta Paradis Bas, "PROCESS FOR THE PRODUCTION OF EXENATIDE AND OF AN EXENATIDE ANALOGUE." U.S. Patent US20110046349, issued February 24, 2011.
n14:hasConcept
n15:M0199975
foaf:page
n17:byetta.htm n18:exenatide.html
n3:Molecular-Formula
n13:271B627B-363D-11E5-9242-09173F13E4C5
n3:Molecular-Weight
n13:271B627A-363D-11E5-9242-09173F13E4C5
n23:hasATCCode
n24:A10BX04
n3:absorption
Following subcutaneous administration to patients with type 2 diabetes, exenatide reaches median peak plasma concentrations in 2.1 hours.
n3:affectedOrganism
Humans and other mammals
n3:casRegistryNumber
141758-74-9
n3:category
n3:clearance
* Apparent cl=9.1 L/hr
n3:containedIn
n19:271B6274-363D-11E5-9242-09173F13E4C5 n19:271B6275-363D-11E5-9242-09173F13E4C5 n19:271B6273-363D-11E5-9242-09173F13E4C5